CombiGene announces a 75-percent guaranteed preference issue of units amounting to 31 million kronor

Aug 22, 2018

The Board of Directors of CombiGene AB (publ) (”CombiGene” or ”the Company”) has
approved a proposal for a preferential rights issue of shares and warrants (”the Offer” or
”the Rights Issue”). Full subscription of the offer will generate about MSEK 31 before
deductions for issuing expenses.

Read more >>

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden

Linked In     Twitter      Facebook